. - Product Pipeline Review - H2 2011” provides a detailed overview on the Romark Laboratories, L.C.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Romark Laboratories, L.C.’s corporate website, SEC filings, investor presentations and featured press releases, both from Romark Laboratories, L.C. and market -specific third party sources, put together by Global Industries Direct’s team.
Scope of the Research
- Romark Laboratories, L.C. - Brief Romark Laboratories, L.C. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Romark Laboratories, L.C. human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Romark Laboratories, L.C. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Romark Laboratories, L.C.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Why Should You Get This Report?
- Evaluate Romark Laboratories, L.C.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Romark Laboratories, L.C. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Romark Laboratories, L.C.’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Romark Laboratories, L.C..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Romark Laboratories, L.C. and identify potential opportunities in those areas.
Pathology Industry in Japan
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Romark Laboratories, L.C. Snapshot 6
Romark Laboratories, L.C. Overview 6
Key Information 6
Key Facts 6
Romark Laboratories, L.C. – Research and Development Overview 7
Key Therapeutic Areas 7
Romark Laboratories, L.C. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Romark Laboratories, L.C. – Pipeline Products Glance 11
Romark Laboratories, L.C. – Late Stage Pipeline 11
Phase III Products/Combination Treatment Modalities 11
Romark Laboratories, L.C. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Romark Laboratories, L.C. – Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Romark Laboratories, L.C. – Drug Profiles 15
Alinia 15
New Thiazolides 17
NT-300 18
RM-5038 19
Romark Laboratories, L.C. – Pipeline Analysis 20
Romark Laboratories, L.C. – Pipeline Products by Therapeutic Class 20
Romark Laboratories, L.C. - Pipeline Products By Target 22
Romark Laboratories, L.C. – Pipeline Products by Route of Administration 24
Romark Laboratories, L.C. – Pipeline Products by Molecule Type 25
Romark Laboratories, L.C. – Recent Pipeline Updates 26
Romark Laboratories, L.C. - Dormant Projects 27
Romark Laboratories, L.C. - Discontinued Pipeline Products 28
Discontinued Pipeline Product Profiles 28
Alinia 28
Alinia 28
NT-300 28
Romark Laboratories, L.C. – Locations And Subsidiaries 29
Head Office 29
Company's Recent Developments 30
Romark Laboratories, L.C., Recent Developments 30
October 22, 2011: Romark Announces Clinical Trial Results For New Influenza Drug Presented At IDSA Meeting 2011 32
April 19, 2010: Romark Announces Data from Clinical Trial of Nitazoxanide in Patients with Genotype 1 Chronic Hepatitis C Who Previously Failed Treatment with Peginterferon Plus Ribavirin 35
April 15, 2010: Romark Announces Data From Clinical Trial Of Nitoxinide In Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 41
April 15, 2010: Romark Announces Data From Phase II Clinical Study Of Nitoxinide In Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 42
May 04, 2010: Romark Announces Final Data from Clinical Trial of Nitazoxanide in Treatment-naïve Patients with Genotype 1 Chronic Hepatitus C 43
May 04, 2010: Romark Announces Final Data From Phase II Trial Of Nitazoxanide In Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 44
February 01, 2010: Romark Initiates Clinical Trial Of Alinia For The Treatment Of Influenza 50
Financial Deals Landscape 52
Romark Laboratories, L.C., Deals Summary 52
Romark Laboratories, L.C., Pharmaceuticals & Healthcare, Deal Details 53
Venture Financing 53
Romark Laboratories Secures Additional US$ 9.6 Mln In Venture Financing 53
Private Equity 55
The D. E. Shaw Invests In Romark Laboratories 55
Laminar Direct Invests In Romark Laboratories 56
Licensing Agreements 58
Chugai Pharmaceutical Signs Licensing Agreement With Romark Laboratories 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 60
List of Tables
Romark Laboratories, L.C., Facts and Figures 6
Romark Laboratories, L.C., Key Facts 6
Romark Laboratories, L.C. – Pipeline by Therapy Area and Indication, H2 2011 8
Romark Laboratories, L.C. – Pipeline by Stage of Development, H2 2011 9
Romark Laboratories, L.C. – Monotherapy Products in Pipeline, H2 2011 10
Romark Laboratories, L.C. – Phase III, H2 2011 11
Romark Laboratories, L.C. - Phase II, H2 2011 12
Romark Laboratories, L.C. – Pre-Clinical, H2 2011 13
Romark Laboratories, L.C. – Discovery, H2 2011 14
Romark Laboratories, L.C. - Pipeline By Therapeutic Class, H2 2011 21
Romark Laboratories, L.C. - Pipeline By Target, H2 2011 23
Romark Laboratories, L.C. – Pipeline By Route of Administration, H2 2011 24
Romark Laboratories, L.C. – Pipeline By Molecule Type, H2 2011 25
Romark Laboratories, L.C. – Recent Pipeline Updates, H2 2011 26
Romark Laboratories, L.C. - Dormant Developmental Projects, 2010 27
Romark Laboratories, L.C. - Discontinued Pipeline Products, 2010 28
Romark Laboratories, L.C., Deals Summary 52
Romark Laboratories Secures Additional US$ 9.6 Mln In Venture Financing 53
The D. E. Shaw Invests In Romark Laboratories 55
Laminar Direct Invests In Romark Laboratories 56
Chugai Pharmaceutical Signs Licensing Agreement With Romark Laboratories 58
List of Figures
Romark Laboratories, L.C. – Pipeline by Therapy Area and Indication, H2 2011 8
Romark Laboratories, L.C. – Pipeline by Stage of Development, H2 2011 9
Romark Laboratories, L.C. – Monotherapy Products in Pipeline, H2 2011 10
Romark Laboratories, L.C. – Pipeline By Therapeutic Class, H2 2011 20
Romark Laboratories, L.C. - Pipeline By Target, H2 2011 22
